Literature DB >> 16449592

Systems analysis of real-world obstacles to successful cervical cancer prevention in developing countries.

Eric J Suba1, Sean K Murphy, Amber D Donnelly, Lisa M Furia, My Linh D Huynh, Stephen S Raab.   

Abstract

Papanicolaou screening is feasible anywhere that screening for cervical cancer, the leading cause of cancer-related death among women in developing countries, is appropriate. After documenting that the Vietnam War had contributed to the problem of cervical cancer in Vietnam, we participated in a grass roots effort to establish a nationwide cervical cancer prevention program in that country and performed root cause analyses of program deficiencies. We found that real-world obstacles to successful cervical cancer prevention in developing countries involve people far more than technology and that such obstacles can be appropriately managed through a systems approach focused on programmatic quality rather than through ideological commitments to technology. A focus on quality satisfies public health goals, whereas a focus on technology is compatible with market forces.

Entities:  

Mesh:

Year:  2006        PMID: 16449592      PMCID: PMC1470502          DOI: 10.2105/AJPH.2004.061606

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  62 in total

Review 1.  Cost-effectiveness analysis in pathology.

Authors:  S S Raab
Journal:  Clin Lab Med       Date:  1999-12       Impact factor: 1.935

2.  Quality management in gynecologic cytology using interlaboratory comparison.

Authors:  B A Jones; D D Davey
Journal:  Arch Pathol Lab Med       Date:  2000-05       Impact factor: 5.534

Review 3.  The introduction of new vaccines into developing countries.

Authors:  R T Mahoney; J E Maynard
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

4.  Implementation and evaluation of a national external quality control program for cervical cytology in Mexico.

Authors:  Ana Flisser; Felipe García-Malo; María de los Angeles Canepa; Susana Doncel; Raquel Espinoza; Ramiro Moreno; Isidro Avila; Gregorio Pérez-Palacios; Roberto Tapia-Conyer; Juan Ramón de la Fuente
Journal:  Salud Publica Mex       Date:  2002 Sep-Oct

5.  Papanicolaou screening in developing countries: an idea whose time has come.

Authors:  Eric J Suba; Stephen S Raab
Journal:  Am J Clin Pathol       Date:  2004-03       Impact factor: 2.493

6.  Preventing cervical cancer in low-resource settings: building a case for the possible.

Authors:  A E Pollack; V D Tsu
Journal:  Int J Gynaecol Obstet       Date:  2005-05       Impact factor: 3.561

7.  Evaluation of a human papillomavirus assay in cervical screening in Zimbabwe.

Authors:  S D Womack; Z M Chirenje; P D Blumenthal; L Gaffikin; J A McGrath; T Chipato; E Ngwalle; K V Shah
Journal:  BJOG       Date:  2000-01       Impact factor: 6.531

8.  Coming to terms with Vietnam: the Viet/American Cervical Cancer Prevention Project.

Authors:  Eric J Suba; Amber D Donnelly; Lisa M Furia; My Linh D Huynh; Stephen S Raab
Journal:  Diagn Cytopathol       Date:  2005-11       Impact factor: 1.582

Review 9.  Prospects for a prophylactic HPV vaccine: rationale and future implications for cervical cancer screening.

Authors:  M E Sherman; M H Schiffman; H Strickler; A Hildesheim
Journal:  Diagn Cytopathol       Date:  1998-01       Impact factor: 1.582

10.  Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia.

Authors:  J Belinson; Y L Qiao; R Pretorius; W H Zhang; P Elson; L Li; Q J Pan; C Fischer; A Lorincz; D Zahniser
Journal:  Gynecol Oncol       Date:  2001-11       Impact factor: 5.482

View more
  16 in total

1.  Public health systems analysis--the transfer of learning between developed and developing countries.

Authors:  Colin Thunhurst
Journal:  Health Care Manag Sci       Date:  2012-02-15

2.  Alliance for cervical cancer prevention: setting the record straight.

Authors:  Jacqueline Sherris; Thomas C Wright; Lynette Denny; Rengaswamy Sankaranarayanan; Amy E Pollack; Harshad Sanghvi; John W Sellors
Journal:  Am J Public Health       Date:  2006-12-28       Impact factor: 9.308

3.  Reconsidering the feasibility of papanicolaou and alternative screening tests for low-resource countries.

Authors:  Vivien Davis Tsu
Journal:  Am J Public Health       Date:  2006-12-28       Impact factor: 9.308

4.  Papanicolaou test in the detection of high-grade cervical lesions: a re-evaluation based on cytohistologic non-correlation rates in 356 concurrently obtained samples.

Authors:  Bhavini Carns; Oluwole Fadare
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

5.  Meeting global health challenges through operational research and management science.

Authors:  Geoff Royston
Journal:  Bull World Health Organ       Date:  2011-07-05       Impact factor: 9.408

6.  Social values and scientific evidence: the case of the HPV vaccines.

Authors:  Kristen Intemann; Inmaculada de Melo-Martín
Journal:  Biol Philos       Date:  2010-01-06       Impact factor: 1.461

7.  Rate of opportunistic pap smear screening and patterns of epithelial cell abnormalities in pap smears in ajman, United arab emirates.

Authors:  Ghaith J Al Eyd; Rizwana B Shaik
Journal:  Sultan Qaboos Univ Med J       Date:  2012-11-20

8.  Structural barriers to screening for and treatment of cervical cancer in Peru.

Authors:  Valerie A Paz-Soldán; Angela M Bayer; Lauren Nussbaum; Lilia Cabrera
Journal:  Reprod Health Matters       Date:  2012-12

9.  Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras.

Authors:  Rebecca B Perkins; Sarah M Langrish; Linda J Stern; James F Burgess; Carol J Simon
Journal:  Womens Health Issues       Date:  2009-11-26

10.  Test group biases and ethical concerns mar New England Journal of Medicine articles promoting HPV screening for cervical cancer in rural India.

Authors:  R Marshall Austin; Chengquan Zhao
Journal:  Cytojournal       Date:  2009-07-16       Impact factor: 2.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.